Eli Lilly and Company $LLY Stock Holdings Lowered by Brookstone Capital Management

Brookstone Capital Management trimmed its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 9.8% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 41,804 shares of the company’s stock after selling 4,521 shares during the period. Brookstone Capital Management’s holdings in Eli Lilly and Company were worth $44,926,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the business. 10Elms LLP lifted its position in shares of Eli Lilly and Company by 33.3% during the 3rd quarter. 10Elms LLP now owns 40 shares of the company’s stock valued at $31,000 after acquiring an additional 10 shares during the last quarter. M.E. Allison & CO. Inc. grew its holdings in shares of Eli Lilly and Company by 0.7% in the 4th quarter. M.E. Allison & CO. Inc. now owns 1,477 shares of the company’s stock worth $1,587,000 after acquiring an additional 10 shares during the last quarter. Bridgewater Advisors Inc. raised its position in shares of Eli Lilly and Company by 0.3% during the third quarter. Bridgewater Advisors Inc. now owns 3,955 shares of the company’s stock worth $3,018,000 after purchasing an additional 11 shares during the period. Manske Wealth Management lifted its holdings in shares of Eli Lilly and Company by 2.5% during the third quarter. Manske Wealth Management now owns 448 shares of the company’s stock valued at $342,000 after purchasing an additional 11 shares during the last quarter. Finally, Guardian Partners Inc. lifted its holdings in shares of Eli Lilly and Company by 0.3% during the third quarter. Guardian Partners Inc. now owns 4,000 shares of the company’s stock valued at $3,302,000 after purchasing an additional 12 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the company. UBS Group reissued a “buy” rating on shares of Eli Lilly and Company in a research note on Wednesday, March 18th. Leerink Partners upped their price objective on shares of Eli Lilly and Company from $1,234.00 to $1,296.00 and gave the company an “outperform” rating in a research note on Thursday, February 5th. Berenberg Bank raised their target price on shares of Eli Lilly and Company from $950.00 to $1,050.00 and gave the stock a “hold” rating in a report on Thursday, February 19th. Scotiabank reissued an “outperform” rating and issued a $1,300.00 target price on shares of Eli Lilly and Company in a research report on Thursday, February 5th. Finally, Jefferies Financial Group set a $1,300.00 price target on shares of Eli Lilly and Company and gave the company a “buy” rating in a report on Friday, March 13th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,221.26.

Eli Lilly and Company Stock Up 3.9%

NYSE:LLY opened at $955.45 on Thursday. The business’s fifty day moving average price is $999.28 and its 200 day moving average price is $966.87. The firm has a market capitalization of $902.73 billion, a price-to-earnings ratio of 41.63, a PEG ratio of 1.07 and a beta of 0.51. The company has a current ratio of 1.58, a quick ratio of 1.19 and a debt-to-equity ratio of 1.54. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, topping analysts’ consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The firm had revenue of $19.29 billion during the quarter, compared to analyst estimates of $17.85 billion. During the same period last year, the company posted $5.32 EPS. The business’s quarterly revenue was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, sell-side analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: FDA approved Lilly’s oral GLP‑1 weight‑loss pill Foundayo — the approval opens a large, fast‑growing obesity market for a convenient daily pill (Lilly will sell Foundayo via LillyDirect with low listed cash prices and broad availability), which drove the stock rally. Lilly’s weight-loss pill wins US approval, sets up next battle with rival Novo Nordisk – reuters.com
• Positive Sentiment: Lilly agreed to acquire Centessa Pharmaceuticals (up to ~$7.8B including milestones) to add orexin/OX2R sleep‑wake assets — diversification into neuroscience reduces concentration risk on GLP‑1s and supports longer‑term growth expectations. Eli Lilly to buy Centessa Pharma in $6.3 billion deal – Reuters
• Positive Sentiment: Unusual bullish options flow — large volume of call buying suggests traders positioned for further upside after the approval/announcements, amplifying intraday momentum. Eli Lilly Pops on GLP‑1 Pill Approval. Should You Buy LLY Stock Here? – Barchart
• Neutral Sentiment: Competitive dynamics — Novo Nordisk is responding with subscription pricing for Wegovy and other tactics; Foundayo’s pricing/coverage and real‑world adoption vs. Wegovy will determine market share, so near‑term upside could be capped by competition. Novo Nordisk (NVO) Stock: New Wegovy Subscription Pricing Takes on Eli Lilly – Blockonomi
• Negative Sentiment: Policy and pricing risk — Lilly’s CEO publicly opposed codifying ‘Most Favored Nations’ drug‑pricing deals into law, highlighting ongoing regulatory/political risks that could pressure pricing or margins over time. Eli Lilly opposes push to pass Trump’s drug pricing deals into law, CEO says – CNBC

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.